A renowned Israeli TV journalist who lost his ability to speak clearly because of ALS is returning to the air using ...

In studies by Massachusetts General Hospital, the AbbVie-Calico collaborative drug and Denali Therapeutics' own drug failed to meet endpoints for treating amyotrophic lateral sclerosis, more widely ...

Neurosense entered a binding term sheet with a global pharmaceutical company to advance development and commercialization of ...

Denali's DNL343 missed efficacy goals in the HEALEY ALS trial but was well-tolerated. Analysts await detailed biomarker data ...

Denali’s medicine and a similar one from Calico Life Sciences and AbbVie were not much different than a placebo, bringing the ...

Primary endpoint of overall function (ALSFRS-R) and survival, and key secondary endpoints of muscle strength and respiratory function, were not ...

Denali Therapeutics said the latest trial of its treatment for amyotrophic lateral sclerosis, or ALS, didn't meet its primary or secondary endpoints after 24 weeks.

Denali Therapeutics (DNLI) announced topline results from an analysis of Regimen G of the Phase 2/3 HEALEY ALS Platform Trial evaluating eIF2B ...

Thanks to awareness-raising initiatives like the Ice Bucket Challenge, we all have a better appreciation of amyotrophic ...

Ancient Viral DNA in the Human Genome Linked to Multiple Sclerosis and Amyotrophic Lateral Sclerosis Oct. 21, 2024 — New research has revealed a connection between ancient viral DNA embedded in ...

Despite the lower ALS risk, heart and metabolism problems are tied to faster disease progression and worse survival in the ...

CVN-293 is under clinical development by Cerevance and currently in Phase I for Amyotrophic Lateral Sclerosis. According to GlobalData, Phase I drugs for Amyotrophic Lateral Sclerosis have an 81% ...